Dihydro-alpha-ergocryptine mesylate (BioDeep_00000839755)
代谢物信息卡片
化学式: C33H47N5O8S (673.3145182000001)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CC5C(CC6=CNC7=CC=CC5=C67)N(C4)C)O.CS(=O)(=O)O
InChI: /m1./s1
描述信息
N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents > N04BC - Dopamine agonists
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists
D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
同义名列表
1 个代谢物同义名
数据库引用编号
10 个数据库交叉引用编号
- ChEBI: CHEBI:31487
- KEGGdrug: D07836
- PubChem: 159729
- ChEMBL: CHEMBL3707289
- MeSH: Dihydroergocryptine
- CAS: 29261-93-6
- CAS: 14271-05-7
- PubChem: 585231
- NIKKAJI: J220.476B
- KEGG: C13167
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Beatriz Bicalho, Juliana Marconi Giolo, Sergio Lilla, Gilberto De Nucci. Identification and human pharmacokinetics of dihydroergotoxine metabolites in man: preliminary results.
Biopharmaceutics & drug disposition.
2008 Jan; 29(1):17-28. doi:
10.1002/bdd.585. [PMID: 17941060] - Christian de Mey, Paraskeva Stamenova, Marin Daskalov, Milka Orozova, Ivan Staikov, Vitan Vlahov, Martina Wangemann. Bioequivalence of a novel high-dose oral formulation of alpha-dihydroergocryptine.
Arzneimittel-Forschung.
2006; 56(3):205-11. doi:
10.1055/s-0031-1296712. [PMID: 16618013] - Gerhard Friedrich, Kurt Appel, Thorsten Rose, Martina Wangemann, Michael Althaus, Klaus Rissler. Determination of dihydroergocryptine in human plasma and urine samples using on-line sample extraction-column-switching reversed-phase liquid chromatography-mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2004 Sep; 808(2):131-9. doi:
10.1016/j.jchromb.2004.03.049. [PMID: 15261806] - G Pöpperl, K Tatsch, E Ruzicka, A Storch, T Gasser, J Schwarz. Comparison of alpha-dihydroergocryptine and levodopa monotherapy in Parkinson's disease: assessment of changes in DAT binding with [123I]IPT SPECT.
Journal of neural transmission (Vienna, Austria : 1996).
2004 Aug; 111(8):1041-52. doi:
10.1007/s00702-004-0147-6. [PMID: 15254792] - Manuela Ehrhardt, Heike Lindenmaier, Juergen Burhenne, Walter Emil Haefeli, Johanna Weiss. Influence of lipid lowering fibrates on P-glycoprotein activity in vitro.
Biochemical pharmacology.
2004 Jan; 67(2):285-92. doi:
10.1016/j.bcp.2003.09.008. [PMID: 14698041] - Christian de Mey, Władyslaw Sułowicz, Tomasz Stompór, Eric Ezan, Angelika Retzow, Michael Althaus. Single dose pharmacokinetics of alpha-dihydroergocryptine in patients with moderate to severe renal insufficiency.
Arzneimittel-Forschung.
2003; 53(11):769-73. doi:
10.1055/s-0031-1299827. [PMID: 14677372] - Kazuto Yasuda, Lu-Bin Lan, Dominique Sanglard, Katryn Furuya, John D Schuetz, Erin G Schuetz. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
The Journal of pharmacology and experimental therapeutics.
2002 Oct; 303(1):323-32. doi:
10.1124/jpet.102.037549. [PMID: 12235267] - D Minea, I Varga, C Falup-Pecurariu, C de Mey, A Retzow, M Althaus. Influence of the dopamine agonist alpha-dihydroergocryptine on the pharmacokinetics of levodopa in patients with Parkinson's disease.
Clinical neuropharmacology.
2001 Jul; 24(4):235-8. doi:
10.1097/00002826-200107000-00008. [PMID: 11479396]